{"filings":[{"id":590677,"accession_number":"0001493152-26-024884","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-05-22T10:03:29+00:00","items":["5.07"],"status":"ready","headline":"MAIA Biotechnology shareholders re-elect two directors, ratify Grant Thornton at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted to re-elect Louie Ngar Yee (16.7M for, 8.8M withheld) and Steven Chaouki (25.1M for, 345.7K withheld) as Class I directors for three-year terms.","Ratification of Grant Thornton LLP as independent auditor for FY 2026 passed with 37.3M for, 210K against, 19K abstentions.","Approximately 61.9% of outstanding shares (37.5M of 60.7M) were represented at the meeting, establishing a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":444717,"accession_number":"0001493152-26-023168","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-05-14T21:02:35+00:00","items":["1.02"],"status":"ready","headline":"MAIA Biotechnology terminates ATM equity offering agreement after raising ~$5.68M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Suspended sales and gave notice to terminate At The Market Offering Agreement with H.C. Wainwright, effective 7 business days after May 14, 2026.","Since March 28, 2025 prospectus supplement for $11.2M, sold 3,116,012 shares for gross proceeds of approx. $5,680,924.","No further sales under the ATM facility; termination will be effective upon expiration of the notice period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96489,"accession_number":"0001493152-26-016989","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.","44 active international sites across Europe/Asia; trial evaluates ateganosine as 3L NSCLC therapy.","$2.3M NIH grant funds third-line evaluation; holds FDA Fast Track designation.","2025 data: eight patients with overall survival beyond 2 years, four over 30 months, one at 33 months.","Approximately 50,000 advanced NSCLC patients in U.S. annually progress to third-line treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96488,"accession_number":"0001493152-26-015662","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.","FDA granted Fast Track designation for ateganosine, a dual mechanism telomere-targeting agent, for third-line NSCLC treatment.","Statistical assessments based on Phase 2 data point to high probability of technical success in Phase 3 full approval trial.","Interim Phase 3 data expected next year; may support FDA discussion for early full commercial approval in third-line NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96487,"accession_number":"0001493152-26-014924","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MAIA Biotechnology awards $362,610 in bonuses to CEO and Head of Finance for capital raise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Vlad Vitoc receives one-time bonus of $312,610 for efforts in recent capital raise.","Head of Finance Jeffrey Himmelreich receives $50,000 one-time bonus for same capital raise.","Bonuses approved March 27, 2026 and paid March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110437,"accession_number":"0001493152-26-013879","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.","One 3rd-line patient survived 33 months vs. expected 5.8 months; four 2nd-line patients survived >30 months vs. SOC 10.5 months.","All patients had failed prior checkpoint inhibitor therapy; 5 of 8 patients have ongoing survival follow-up.","Phase 3 pivotal trial and Part C expansion (up to 48 patients in Asia/Europe) are enrolling.","Press release references a $50B+ global immunotherapy market as target opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110436,"accession_number":"0001493152-26-013088","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.","Data from THIO-101 trial: Ateganosine + ICI in relapsed NSCLC patients.","Poster title indicates sustained response and long-term therapeutic benefits after treatment cessation.","No financial or numerical efficacy data disclosed in the 8-K; poster available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110435,"accession_number":"0001493152-26-008897","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 20M shares at $1.50/sh, gross proceeds $30M.","Underwriters granted 30-day option to buy up to 3M additional shares for over-allotments.","Net proceeds to fund clinical trials and working capital; offering closed March 4, 2026.","Konik Capital Partners acted as sole book-running manager; 60-day lock-up for insiders.","Offering structured as common stock only with no warrant coverage; led by healthcare investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110434,"accession_number":"0001493152-26-007831","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.","FDA Fast Track designation provides clear regulatory pathway for ateganosine.","First and only direct telomere-targeting anticancer agent in clinical development.","Targets ~50,000 US patients annually in 3L NSCLC with no established standard of care.","CEO Vlad Vitoc cites $50 billion global immunotherapy market opportunity in letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110433,"accession_number":"0001493152-26-002883","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.","Initiated THIO-104 Phase 3 trial in 3L NSCLC; Phase 2 Part C expansion underway in Asia and Europe.","Awarded $2.3M NIH grant for Phase 2 trial; raised ~$17.6M in 2025 capital raises with board participation.","Targeted 2026 milestones: interim efficacy data from Phase 3, completion of Phase 2 Part C, and start of Phase 1 for second-generation molecules.","Company claims ateganosine is the only telomere-targeting anticancer agent in clinical development globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110432,"accession_number":"0001493152-26-002085","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology presents at Biotech Showcase; no specific financial updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management presented at Biotech Showcase in San Francisco on January 13, 2026.","Presentation materials filed as Exhibit 99.1 and posted on company website.","No material financial or operational guidance changes were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127033,"accession_number":"0001493152-25-028041","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology announces $1.51M private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.51M from 1,233,488 shares at $1.224 each, with warrants exercisable at $1.36.","Warrants exercisable six months after issuance, three-year term, priced at NYSE American minimum price.","Directors subscribe for 179,737 shares (~$220k); Louie Ngar Yee, Stan Smith, Steven Chaouki.","Net proceeds to fund Step 1 of Part C of Phase II THIO-101 trial and working capital.","Expected close Dec 18, 2025; securities unregistered, offered under Section 4(a)(2)/Reg D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127032,"accession_number":"0001493152-25-027244","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.","Trial targets up to 300 patients with primary endpoint of overall survival; screening underway in Taiwan, Turkey, EMA countries, Georgia.","CEO Vitoc and board purchased ~182,445 shares on open market Nov 21–28, 2025; insiders now hold 12.95% of company.","Phase 2 data showed median OS 17.8 months vs ~6 months for chemo; FDA granted Fast Track designation for ateganosine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127031,"accession_number":"0001493152-25-027072","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.","Initiating Phase 3 THIO-104 trial for advanced NSCLC without actionable mutations and CPI-refractory.","FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.","NSCLC market valued at $34.1B, projected to nearly double to $68.8B by 2033.","Keytruda generated $29.5B revenue in 2024, with ~30% from NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127030,"accession_number":"0001493152-25-024556","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotech highlights 12 patients enrolled in THIO-101 Phase 2 expansion, 30-month survival at SITC 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.","Phase 3 THIO-104 screening has begun; CEO cites 17.8 months median OS observed in Phase 2 as potential basis for early FDA approval.","A patient treated in March 2023 showed survival of 30 months (912 days) as of September 17, 2025.","Posters presented at SITC 2025 detail Phase 2 and Phase 3 trial designs for ateganosine + cemiplimab in advanced NSCLC.","FDA has granted Fast Track designation for ateganosine in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127029,"accession_number":"0001493152-25-024402","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA starts Romania enrollment for Phase 2 THIO-101 Part C; 38% ORR vs standard 6% cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO presented at Smart Diaspora 2025; Romania begins screening patients for THIO-101 Part C.","Observed 38% overall response rate vs current third-line NSCLC treatments with ~6% response rate.","FDA Fast Track Designation for ateganosine received in July 2025, supports accelerated approval path.","Third-line NSCLC patients resistant to chemo and immunotherapy are target population.","Investigator Tudor Ciuleanu, MD, PhD, is key opinion leader in Eastern Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127028,"accession_number":"0001493152-25-021195","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology presents THIO-104 and THIO-101 posters at SITC 2025 for NSCLC trials","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["THIO-104 Phase 3 study of ategano sine (THIO) sequenced with ICI vs SOC chemo in ICI-resistant advanced NSCLC presented Nov 7.","THIO-101 Phase 2 study of THIO combined with ICI in advanced NSCLC resistant to prior ICI and chemo presented Nov 10.","Posters are in-progress trial updates and contain forward-looking statements; detailed results not disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127027,"accession_number":"0001493152-25-019748","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA enrolls first five patients in THIO-101 Part C expansion in Taiwan and Turkey","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presented trial-in-progress poster on ateganosine (THIO) plus ICI for advanced NSCLC at AACR-NCI-EORTC conference, Oct 22-26, 2025 in Boston.","Enrolled first five patients in Part C (expansion) of THIO-101 Phase 2 trial from Taiwan and Turkey.","Trial evaluates ateganosine (THIO) followed by cemiplimab in 3L NSCLC patients resistant to prior checkpoint inhibitor and chemo.","Screening ongoing in Europe and Asia with multi-continental sites; safety profile aligned with earlier parts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127026,"accession_number":"0001493152-25-019315","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA presents THIO-101 Phase 2 poster at AACR-NCI-EORTC conference on Oct 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Poster on Ateganosine (THIO) + ICI in advanced NSCLC patients resistant to prior ICI and chemotherapy.","Presented at AACR-NCI-EORTC Molecular Targets Conference in Boston.","No specific efficacy or safety data disclosed in the 8-K filing.","Company provided forward-looking statements caution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127025,"accession_number":"0001493152-25-019014","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.","THIO-101 Phase 2 trial evaluates ateganosine + cemiplimab in checkpoint-inhibitor-resistant advanced NSCLC.","New Phase 3 THIO-104 trial compares ateganosine+ICI vs chemotherapy in ICI-resistant NSCLC.","Posters presented at ESMO 2025 in Berlin; full posters available on MAIA website.","CEO states >2-year survival is a clear signal of ateganosine's efficacy in eliminating NSCLC tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127024,"accession_number":"0001493152-25-017948","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","3.02","8.01"],"status":"ready","headline":"MAIA Biotechnology announces $736,600 private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 603,769 shares at $1.22 per share with warrants to purchase 603,769 shares at $1.52.","Gross proceeds ~$736,600; warrants exercisable after six months, three-year term.","Proceeds to fund Step 1 of Part C of Phase II trial THIO-101 for NSCLC and for working capital.","Closing expected October 15, 2025; securities issued as restricted, no registration rights.","Offering exempt under Section 4(a)(2)/Reg D; shares and underlying not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127023,"accession_number":"0001493152-25-017222","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology to hold up to 90% of liquid assets in Bitcoin, Ethereum, and USDC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to 90% of liquid assets to be held in cryptocurrencies: BTC, ETH, and USDC.","Initial tokens: Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC).","Company intends to form a Digital Assets Advisory Board to support strategy.","CEO Vlad Vitoc cites disciplined approach targeting highest-quality tokens for strong returns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143826,"accession_number":"0001493152-25-016200","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology announces $2.25M private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.25M from sale of 1,733,766 shares at $1.30; one warrant per share at $1.57 exercise price.","Funds will support Step 1 of Part C of Phase II trial THIO-101 and working capital.","Greater than 5% holder FGMK subscribed for 769,230 shares & warrants for ~$1M; director Stan Smith for 19,230 shares.","Existing warrants for 1,396,667 shares amended to reduce exercise price from $1.87 to $1.30.","Closing expected on or about October 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143825,"accession_number":"0001493152-25-014729","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.","Grant funds enrollment of US patients resistant to chemo/immunotherapy; distributed over 3 years (2025-2027).","First US patient enrollment to begin immediately following 2023 FDA IND clearance; first expansion patient dosed July 2025 in Taiwan.","Median overall survival for 22 third-line patients was 17.8 months (June 30, 2025) vs 5-6 months for standard chemo.","Grant is non-dilutive funding from NIH's National Cancer Institute (Award R44CA309843)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143824,"accession_number":"0001493152-25-014100","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"MAIA Biotechnology induces warrant exercise at $1.30/share for ~$573K gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered inducement letters for holders to exercise 440,503 warrants at reduced price of $1.30/share.","Gross proceeds estimated at ~$572,654 before expenses; closing expected Sept 22, 2025.","Participating holders include FGMK Business Holdings (243,470 warrants) and David Smith (40,000 warrants).","Net proceeds to be used for general corporate purposes.","Shares issued as restricted securities under exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143823,"accession_number":"0001493152-25-013190","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology posts updated business presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted September 12, 2025; no specific changes disclosed.","Document is forward-looking; Company disclaims obligation to update.","No financial or operational details from presentation available in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143822,"accession_number":"0001493152-25-013074","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.","Estimated median OS of 17.8 months (95% CI lower bound 12.5 months), consistent with prior readout.","2 patients completed 33 cycles, suggesting extended dosing and tolerability for ateganosine.","Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143821,"accession_number":"0001493152-25-012769","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MAIA presents Phase 2 THIO-101 poster at WCLC showing PFS improvement in advanced NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Poster titled 'Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS' presented at 2025 WCLC on Sept 7, 2025.","Data from Phase 2 THIO-101 trial evaluating THIO + cemiplimab in advanced NSCLC patients who failed ≥2 prior therapies.","Specific efficacy numbers (e.g., median PFS, response rates) not disclosed in the filing; poster available on company website Sept 8.","No safety or additional endpoints described in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143820,"accession_number":"0001641172-25-023349","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology granted European patent covering ateganosine-based telomere-targeting anticancer therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.","Patent titled 'Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere'; invented by CSO Sergei Gryaznov and SAB member Jerry Shay.","MAIA's global IP portfolio now includes 10 issued patents worldwide, validated in 19 European countries, and 24 pending applications.","Next-generation telomere-targeting agents aim to improve specificity toward cancer cells and increase anticancer activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143819,"accession_number":"0001641172-25-021105","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotech gets FDA Fast Track for ateganosine in NSCLC; Phase 2 data shows 17.8-month median OS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation for ateganosine (THIO) for treatment of non-small cell lung cancer.","Phase 2 THIO-101 trial showed median overall survival of 17.8 months in heavily pre-treated patients, vs. 5-6 months for standard of care.","Ateganosine is a first-in-class small molecule telomere-targeting agent; if approved, could compete in $34B NSCLC market.","Fast Track enables accelerated approval and priority review; FDA decision possible as early as next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143818,"accession_number":"0001641172-25-020043","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA announces peer-reviewed publication validating second-gen ateganosine prodrugs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data published in Nucleic Acids Research (Vol. 53, Issue 12, June 26, 2025) on novel telomere-targeting dinucleotide prodrugs.","Lead candidates MAIA-2022-12 and MAIA-2021-20 showed strongest in vivo anticancer efficacy and immune-memory responses.","Combination with immune checkpoint inhibitor yielded significantly lower IC50 and superior efficacy vs monotherapy.","Company plans to advance one candidate into human clinical trials after completing GLP-toxicity studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143817,"accession_number":"0001641172-25-018398","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA doses first patient in Phase 2 expansion for ateganosine in advanced NSCLC; median OS 17.8 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.","Median overall survival of 17.8 months observed in 22 patients (95% CI lower bound 12.5 months) in third-line setting.","Expansion includes two arms: ateganosine+cemiplimab (Libtayo) and monotherapy; screening in Europe/Asia.","Regeneron supplies Libtayo for combination cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162095,"accession_number":"0001641172-25-016574","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"MAIA Biotechnology enters $587,905 stock purchase agreement with Prevail Partners for Phase 3 THIO trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.","Share price set at 120% of 30-day VWAP; minimum share price of $1.74; maximum shares issuable at minimum price: 337,876.","Shares are unregistered, issued under Section 4(a)(2); subject to 19.99% blocker and Exchange Cap.","Proceeds used to fund a multicenter Phase 3 study of THIO sequenced with cemiplimab in advanced NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162094,"accession_number":"0001641172-25-016235","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA appoints HCC specialists to SAB; Phase 2 trial enrollment expected by year-end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Drs. Claudia Fulgenzi and David J. Pinato to SAB; both are HCC clinician-scientists.","Planning Phase 2 trial of ateganosine (THIO) plus checkpoint inhibitor in hepatocellular carcinoma (HCC).","Expects to begin enrolling HCC trial patients by end of 2025 upon obtaining regulatory approvals.","FDA granted Orphan Drug Designation for ateganosine in HCC in 2022, potentially 7-year market exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162093,"accession_number":"0001641172-25-015524","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.","Preclinical data showed ateganosine highly synergistic and effective with anti-PD-L1 agent atezolizumab.","Ateganosine is a first-in-class telomere-targeting agent in clinical development for NSCLC after checkpoint inhibitor progression.","CEO Vlad Vitoc said partnership with Roche strengthens mission to find safe and effective cancer treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162092,"accession_number":"0001641172-25-015410","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"MAIA Biotechnology raises ~$329K via warrant exercise inducement at reduced $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 17, 2025, MAIA entered inducement letters with holders of four warrant series to exercise for cash at reduced exercise price of $1.50 per share.","Total warrants exercised: 219,283 shares; expected gross proceeds of approximately $328,925.","Closing expected on or about June 18, 2025; proceeds for general corporate purposes.","Shares issued as restricted securities exempt under Section 4(a)(2), Rule 506, and/or Section 3(a)(9) of the Securities Act.","Participating holders include Pre-IPO, March 2024, November 2024, and December 2024 warrant holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162091,"accession_number":"0001641172-25-013803","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.","95% CI lower bound of 12.5 months and 99% CI lower bound of 10.8 months shown.","New partial response (>=30% tumor reduction) observed after >20 months on treatment.","Longest-surviving patient reached 24.3 months and completed 32 cycles of therapy.","Potential FDA decision for ateganosine as early as next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162090,"accession_number":"0001641172-25-013176","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.","Trial evaluates THIO sequenced with CPI cemiplimab in advanced NSCLC patients after 2+ prior therapies.","Corporate presentation posted to MAIA website on June 2, 2025, filed as Exhibit 99.2.","Poster available on MAIA's website from June 2, 2025 onward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162089,"accession_number":"0001641172-25-012617","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","3.02","8.01"],"status":"ready","headline":"MAIA Biotechnology closes $695K private placement of stock and warrants for THIO-101 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 463,332 shares and warrants at $1.50/share; warrants exercisable at $1.71, 5-year term, 6-month lockout.","Director Stan Smith purchased 33,333 shares and warrants for ~$50,000.","Gross proceeds ~$695,000; net proceeds to fund Step 1 of Part C of Phase II THIO-101 trial and working capital.","Expected closing May 29, 2025; securities exempt from registration under Section 4(a)(2)/Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162088,"accession_number":"0001641172-25-012192","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"MAIA Biotechnology increases authorized shares from 70M to 150M after stockholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to certificate of incorporation on May 22, 2025.","Certificate of Amendment filed with Delaware Secretary of State on same date.","Authorized common stock raised from 70,000,000 to 150,000,000 shares.","CEO Vlad Vitoc signed the filing on May 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162087,"accession_number":"0001641172-25-012079","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology stockholders approve increase in authorized common shares to 150M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected Class III directors Jean-Manassé Theagène and Stan V. Smith for three-year terms.","Ratified Grant Thornton LLP as independent auditor for FY2025.","Approved amendment to increase authorized common stock from 70M to 150M shares.","Certificate of Amendment filed on May 22, 2025, effecting the share increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162086,"accession_number":"0001641172-25-008750","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MAIA raises $1.08M in private placement; warrants corrected to 1-year lockout, 6-year term","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["719,999 shares sold at $1.50/share; each with a warrant to buy one share at $2.05.","Warrants exercisable starting 1 year from issuance, expiring 6 years from issuance date.","Directors Stan Smith ($100K) and Ramiro Guerrero ($30K) participated in the offering.","Net proceeds to fund Part C of THIO-101 Phase II trial and working capital.","Closing expected on or about May 7, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162085,"accession_number":"0001641172-25-005692","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology posts business presentation; no specific details in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made business presentation available on its website on April 22, 2025.","Presentation is filed as Exhibit 99.1 to this 8-K, but content not provided in the filing excerpt.","Presentation speaks as of date of report; company disclaims obligation to update.","Forward-looking statements included; no material financial or operational updates disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162084,"accession_number":"0001641172-25-002001","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.","Phase 2 THIO-101 expansion underway; potential accelerated approval filing in 2026.","Phase 3 THIO-104 set to begin mid-2025; potential full approval filing in 2026.","Multiple THIO trials planned in additional cancer indications.","Significant market opportunity in hard-to-treat cancers with unmet medical needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180113,"accession_number":"0001641172-25-001045","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.","Trial evaluates THIO sequenced with cemiplimab in advanced NSCLC patients after 2+ prior therapies.","Poster copy filed as Exhibit 99.1 and posted on company website; no specific numeric results in 8-K text.","Data disclosure under Regulation FD; forward-looking statements caution against undue reliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180112,"accession_number":"0001641172-25-000788","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology reduces ATM offering capacity from $30M to $11.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price reduced from $30M to $11.2M under ATM with H.C. Wainwright.","Prior sales: $6.29M in last 12 months, $11.63M total under the agreement.","Prospectus supplement dated March 26, 2025 filed for the $11.2M offering.","No reason given for reduction; company continues at-the-market program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180111,"accession_number":"0001641172-25-000154","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology posts business presentation; no substantive updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made a business presentation available on its website on March 21, 2025.","Presentation contains forward-looking statements; no specific operational or financial updates detailed in the 8-K.","MAIA disclaims obligation to update the presentation; it speaks only as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180110,"accession_number":"0001493152-25-010925","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA Biotech gets USAN approval for 'ateganosine' as generic name for THIO in NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["USAN Council approved nonproprietary name 'ateganosine' for lead molecule THIO, a telomere-targeting anticancer agent.","Naming is an essential step in FDA approval process for THIO in advanced non-small cell lung cancer (NSCLC).","MAIA will retain THIO name for clinical trial designations (THIO-101, THIO-102, THIO-103, THIO-104).","No financial terms disclosed; no change in guidance or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180109,"accession_number":"0001493152-25-008540","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MAIA plans Phase 3 pivotal trial of THIO+CPI vs chemo in NSCLC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial THIO-104 to enroll up to 300 patients with third-line NSCLC.","Primary endpoint is overall survival; THIO sequenced with checkpoint inhibitor vs investigator's choice chemo.","Patient enrollment expected to begin H2 2025 in Asia, Europe, and U.S.","Based on THIO-101 Phase 2 data that consistently outperformed standard options.","Trial designed to support FDA commercial approval of THIO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180108,"accession_number":"0001493152-25-008137","cik":1878313,"company_name":"MAIA Biotechnology, Inc.","ticker":"MAIA","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MAIA Biotechnology raises ~$1.43M private placement, total $4.1M from two deals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["952,300 shares at $1.50 each; warrants exercisable at $1.85 for 6 years, starting 1 year post-issuance.","Company directors participate (58,333 shares); proceeds to fund Part C of Phase 2 THIO-101 trial and working capital.","Combined gross proceeds from this and a separate $2.7M placement (closed Feb 24) reach $4.1M.","Private placement expected to close on or about February 26, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79040982.44274808,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-02-25T23:59:59+00:00|180108"}